Myc and its interactors take shape
2015 (English)In: Biochimica et Biophysica Acta. Gene Regulatory Mechanisms, ISSN 1874-9399, E-ISSN 1876-4320, Vol. 1849, no 5, 469-483 p.Article, review/survey (Refereed) Published
The Myc oncoprotein is a key contributor to the development of many human cancers. As such, understanding its molecular activities and biological functions has been a field of active research since its discovery more than three decades ago. Genome-wide studies have revealed Myc to be a global regulator of gene expression. The identification of its DNA-binding partner protein, Max, launched an area of extensive research into both the protein-protein interactions and protein structure of Myc. In this review, we highlight key insights with respect to Myc interactors and protein structure that contribute to the understanding of Mycs roles in transcriptional regulation and cancer. Structural analyses of Myc show many critical regions with transient structures that mediate protein interactions and biological functions. Interactors, such as Max, TRRAP, and PTEF-b, provide mechanistic insight into Mycs transcriptional activities, while others, such as ubiquitin ligases, regulate the Myc protein itself. It is appreciated that Myc possesses a large interactome, yet the functional relevance of many interactors remains unknown. Here, we discuss future research trends that embrace advances in genome-wide and proteome-wide approaches to systematically elucidate mechanisms of Myc action. This article is part of a Special Issue entitled: Myc proteins in cell biology and pathology. (C) 2014 Elsevier B.V. All rights reserved.
Place, publisher, year, edition, pages
Elsevier , 2015. Vol. 1849, no 5, 469-483 p.
Myc; Protein-protein interaction; Protein structure; Transcriptional regulation; Post-translational modification; Cancer
Biochemistry and Molecular Biology
IdentifiersURN: urn:nbn:se:liu:diva-118983DOI: 10.1016/j.bbagrm.2014.06.002ISI: 000354581400002PubMedID: 24933113OAI: oai:DiVA.org:liu-118983DiVA: diva2:818171
Funding Agencies|Canadian Cancer Society Research Institute [018298, 020276]; Canadian Institutes of Health Research [MOP-275788]; Swedish Cancer Society [13 0736]; Swedish Childhood Cancer Foundation [PROJ12/073]; Swedish Research Council [621-2012-5250]; Swedish e-Science Research Center [VR 621-2012-5270, CTS 12:516]; Ontario Research Fund [GL2-01-030]; Canada Research Chair Program2015-06-082015-06-052015-06-24